CO2022015810A2 - Variante de adamts13, composiciones y usos de estas - Google Patents
Variante de adamts13, composiciones y usos de estasInfo
- Publication number
- CO2022015810A2 CO2022015810A2 CONC2022/0015810A CO2022015810A CO2022015810A2 CO 2022015810 A2 CO2022015810 A2 CO 2022015810A2 CO 2022015810 A CO2022015810 A CO 2022015810A CO 2022015810 A2 CO2022015810 A2 CO 2022015810A2
- Authority
- CO
- Colombia
- Prior art keywords
- adamts13
- variant
- compositions
- variants
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se relaciona con las variantes de ADAMTS13 y los métodos para administrar las variantes de ADAMTS13 para tratar una enfermedad o padecimiento asociado con ADAMTS13 y con la disfunción del VWF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004389P | 2020-04-02 | 2020-04-02 | |
PCT/IB2021/000210 WO2021198781A2 (en) | 2020-04-02 | 2021-04-02 | Adamts13 variant, compositions, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022015810A2 true CO2022015810A2 (es) | 2022-11-18 |
Family
ID=75870668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0015810A CO2022015810A2 (es) | 2020-04-02 | 2022-11-02 | Variante de adamts13, composiciones y usos de estas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230203469A1 (es) |
EP (1) | EP4127158A2 (es) |
JP (1) | JP2023521658A (es) |
KR (1) | KR20230005192A (es) |
CN (1) | CN115836126A (es) |
AU (1) | AU2021248679A1 (es) |
BR (1) | BR112022019817A2 (es) |
CA (1) | CA3173709A1 (es) |
CO (1) | CO2022015810A2 (es) |
MX (1) | MX2022012303A (es) |
WO (1) | WO2021198781A2 (es) |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
DK1902141T3 (da) | 2005-06-17 | 2012-05-07 | Baxter Int | ADAMTS 13-holdige sammensætninger med thrombolytisk virkning |
RU2486236C2 (ru) | 2006-01-04 | 2013-06-27 | Бакстер Интернэшнл Инк. | Способ экспрессии белка |
US20090203140A1 (en) | 2007-09-27 | 2009-08-13 | Sangamo Biosciences, Inc. | Genomic editing in zebrafish using zinc finger nucleases |
US20090317375A1 (en) | 2008-05-12 | 2009-12-24 | Immune Disease Institute, Inc. | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
CN104962539B (zh) | 2009-07-31 | 2019-09-17 | 百深公司 | 用于adamts蛋白表达的细胞培养基 |
EP4218797A1 (en) | 2009-09-21 | 2023-08-02 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized adamts13 formulations |
EP2497547B1 (en) | 2011-03-08 | 2018-06-27 | Nintendo Co., Ltd. | Information processing program, information processing apparatus, information processing system, and information processing method |
AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
GB201510870D0 (en) | 2015-05-26 | 2015-08-05 | Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh | Treatment of infarction |
CN109789192B (zh) | 2016-08-04 | 2023-04-07 | 武田药品工业株式会社 | 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象 |
EP3999104A4 (en) * | 2019-06-07 | 2023-08-09 | Takeda Pharmaceutical Company Limited | USE OF RECOMBINANT ADAMTS13 TO TREAT SICKLE CELL DISEASE |
-
2021
- 2021-04-02 EP EP21724362.5A patent/EP4127158A2/en active Pending
- 2021-04-02 KR KR1020227037798A patent/KR20230005192A/ko active Search and Examination
- 2021-04-02 AU AU2021248679A patent/AU2021248679A1/en active Pending
- 2021-04-02 BR BR112022019817A patent/BR112022019817A2/pt unknown
- 2021-04-02 US US17/916,441 patent/US20230203469A1/en active Pending
- 2021-04-02 WO PCT/IB2021/000210 patent/WO2021198781A2/en unknown
- 2021-04-02 CA CA3173709A patent/CA3173709A1/en active Pending
- 2021-04-02 JP JP2022560179A patent/JP2023521658A/ja active Pending
- 2021-04-02 CN CN202180039464.1A patent/CN115836126A/zh active Pending
- 2021-04-02 MX MX2022012303A patent/MX2022012303A/es unknown
-
2022
- 2022-11-02 CO CONC2022/0015810A patent/CO2022015810A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023521658A (ja) | 2023-05-25 |
US20230203469A1 (en) | 2023-06-29 |
MX2022012303A (es) | 2022-11-30 |
BR112022019817A2 (pt) | 2022-12-06 |
KR20230005192A (ko) | 2023-01-09 |
CN115836126A (zh) | 2023-03-21 |
CA3173709A1 (en) | 2021-10-07 |
WO2021198781A3 (en) | 2021-11-11 |
WO2021198781A2 (en) | 2021-10-07 |
AU2021248679A1 (en) | 2022-10-27 |
EP4127158A2 (en) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22061711A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
CL2021003306A1 (es) | Agentes, usos y métodos para el tratamiento de la sinucleinopatía. (divisional de solicitud nº 201901293) | |
CO2022015170A2 (es) | Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas | |
ECSP12012171A (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos | |
CL2022000195A1 (es) | Usos para tratar la enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
ECSP21051833A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
CO2023003576A2 (es) | Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y métodos de uso de las mismas | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
CL2019001658A1 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
CL2018003260A1 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
PE20200336A1 (es) | Formulaciones a largo plazo | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
CO2023013465A2 (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
UY39504A (es) | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión | |
CL2019002031A1 (es) | Moduladores del canal de potasio. | |
CO2022015810A2 (es) | Variante de adamts13, composiciones y usos de estas | |
CL2020001353A1 (es) | Pirazolopirimidinas que tienen actividad contra el vsr. |